Significant reduction found in risk for disease progression\/death for C+R versus placebo and rituximab<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 13, 2021 (HealthDay News) — Copanlisib plus rituximab (C+R) reduces disease progression or death in patients with relapsed indolent non-Hodgkin lymphoma (iNHL), according to a study presented during Week 1 of the annual meeting of the American Association for Cancer Research, held virtually from April 10 to 15.<\/p>\n
Matthew J. Matasar, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues reported primary data from the phase III study of C+R versus placebo (P)+R in patients with relapsed iNHL. Overall, 307 and 151 patients were randomly assigned to C+R and P+R, respectively.<\/p>\n
The researchers found that during a median follow-up of 19.2 months, the primary study end point of progression-free survival was 21.5 versus 13.8 months in the C+R and P+R groups, respectively, with a significant reduction in the risk for disease progression\/death for C+R versus P+R (hazard ratio, 0.52). Reductions were seen across histology subtypes. Objective response rates (ORRs) were 80.8 and 47.7 percent for C+R and P+R, respectively, while complete response rates (CRRs) were 33.9 and 14.6 percent, respectively. Across all iNHL subtypes, the ORRs and CRRs were higher with C+R treatment. Hyperglycemia, hypertension, and diarrhea were the most common treatment-emergent adverse events for patients receiving C+R (69.4, 49.2, and 33.6 percent, respectively). Rates of serious adverse events were higher with C+R versus P+R (47.2 versus 18.5 percent).<\/p>\n
“The CHRONOS-3 trial met its primary end point of progression-free survival, with improved outcomes seen in several subtypes of indolent lymphoma included in the study,” Matasar said in a statement.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Bayer AG, which manufactures copanlisib and funded the trial.<\/p>\n
Press Release<\/a><\/p>\n